“We are delighted to collaborate with Venus Remedies, a renowned Indian company, with a shared purpose and commitment to develop more effective antibiotics to combat the escalating global AMR crisis. India has among the highest levels of multidrug resistance in the world. By using AdjuTec Pharma’s technology we have shown that we can restore the efficacy of meropenem in the vast majority of meropenem-resistant Enterobacterales in this Indian collection. AdjuTec Pharma is thrilled to continue its preclinical collaboration with Venus Remedies. This aligns perfectly with our strategy of partnering with leading and international pharmaceutical companies to bring our technologies to market.”
“We are committed to addressing AMR by building strong international partnerships that accelerate anti-infectives innovation and strengthen the global response to multidrug-resistant infections. We are pleased to partner with AdjuTec Pharma, and APC-301 appears promising against MBL-producing Enterobacterales. We believe partnerships like these are critical to translating high-quality science into meaningful clinical impact, and we remain open to supporting the development of promising candidates that can improve treatment options in areas of high unmet medical need.”